ResMed Beat, Launched a Mask, Killed a Ventilator — And Told You to Expect the Midpoint

A 28.7% ninety-day melt-up into a quarter whose real story is a fabric cushion, a patient funnel that hasn't paid off yet, and a multiple that finally fits the earnings

RMD · Earnings Call · 2026-10-29

The tape got ahead of the print

ResMed walked into this report having rallied 28.7% over 90 trading days in one unbroken up-segment — no drawdown inside the window — yet the stock still sits about 15% below the $297.36 all-time high printed in September 2021. That combination is the puzzle of this quarter. For five years the company has been working off a bubble multiple: price-to-net-income peaked at 76.8x in 2021Q3 and now sits at 18.5x, down 32% year over year. The rally is not a re-rating. It is earnings finally catching a price that stopped moving. The quarter itself was clean: revenue of $1.4 billion, up 6% reported and 7% on a core constant-currency basis; non-GAAP EPS of $2.91, up 14%; gross margin 62.5%, up 50 basis points; and more than $1 billion returned to shareholders — a record — through a $936 million buyback plus the dividend, funded largely by the MatrixCare divestiture. Free cash flow of $374 million was down year over year on a deliberate inventory build and cash tax prepays, consistent with the longer-run pattern in free cash flow less stock comp, which fell 22% year over year to $376 million last fiscal year-end.

What actually changed: the interface, not the machine

AirTouch F40 launched this week — ResMed's third fabric mask, and its first in the full-face category, the roughly 30% of patients who breathe through the mouth at night. Mick Farrell did not sell it on comfort alone; he sold it on data: 91% of patients rated it comfortable at first fitting, and the earlier fabric masks have now shown a 6% adherence uplift versus their silicone equivalents. “We've now got real-world data to show a 6% increase in adherence for those first launched, now 12, 18 months in market masks.” — Michael J. Farrell, Chief Executive Officer and Chairman of the Board · 2026-10-29 That is a meaningful shift in the argument. Six months ago the same product family came with an unresolved commercial objection: an analyst flatly asked whether the fabric price point left a traditional HME unable to make money on setup or resupply, making the compliance benefit commercially irrelevant. Farrell conceded it was payer-dependent:

It depends on the payer landscape. There are 50 states and multiple payers per state... we price for what is right in terms of the extra cost that goes into those fabrics but also the extra value that we see.
Michael J. Farrell, Chief Executive Officer · 2026-04-30

Now the pitch is adherence plus a premium full-face SKU — a real-world adherence argument instead of a comfort argument. Tellingly, the phrase ResMed used for six straight quarters to describe fabric masks — that they were "changing the basis of competition" — did not survive into this transcript. The company stopped asserting it and started measuring it.

The funnel: the real bet, and the admission attached to it

The strategic center of gravity has moved from hardware refresh to middle of funnel conversion. MyAir has passed 13 million downloads; the generative-AI sleep coach Dawn has logged 2.1 million patient inquiries, up over 40% sequentially; SmartComfort, an FDA-cleared AI comfort-adjustment feature, is producing a 4.3% lift in 30-day compliance; CME programming has been completed roughly 108,000 times by 63,000 clinicians; and consumer partnerships with Oura and Eight Sleep are now sourcing warm leads — about 28,000 Oura users have clicked through to resmed.com, 72% of them previously undiagnosed. And yet the honest answer to whether any of it moved the quarter was no. “As for driving material contributions in Q1, no, not yet. But watch this space... No material contribution in Q1, but as we look at fiscal year, I hope to be here in 12 months' time talking about some good material contribution from our marketing programs.” — Michael J. Farrell, Chief Executive Officer and Chairman of the Board · 2026-10-29 CFO Aaron Bloomer was equally blunt that the 5%–7% guide leans on outcomes not yet delivered: net price realization that is "very modest," marketing that is "going to take some time," and a France fleet refresh that is a first-half tailwind and a second-half headwind. Which is why the guidance decision is the most interesting line in the release. Q1 came in at 7% — the top of the range — with EPS up 14% against a 7%–10% full-year guide. And management reiterated anyway, with a pointed steer to the middle: “I want to reiterate that the most likely outcome is still the midpoint of our guide when we go 5%-7%.” — Aaron Bloomer, Chief Financial Officer · 2026-10-29 A stock up 28.7% into a beat-and-hold is not being paid for this quarter. It is being paid for the funnel and the fabric, on faith.

What management stopped talking about

The quietest event of the quarter was the loudest strategically: ResMed will no longer sell the Astral device. Life-support device revenue fell 94% in the Americas and 79% in the rest of world, and the company is now allocating every available component to servicing existing patients instead of shipping new units. The financials are already framed: a $75 million revenue headwind, roughly 130 basis points on the year, with core growth ex-Astral quoted at 6.3%–8.3%. The tone was pure reputational management:

We're going to execute the best recall in the history of life support ventilation. We took $42 million reserve, and I've seen the latest data and it's very good.
Michael J. Farrell, Chief Executive Officer and Chairman of the Board · 2026-10-29

Equally notable is what vanished from the innovation narrative. In the prior quarter, AirSense 11 was the single most prominent company keyword, and analysts were pressing on the five-year platform cycle and what comes next. Farrell refused to engage then — “I don't talk about future product pipelines, and you obviously sort talking about, hey, after AirSense 11, what does AirSense 12 look like and when would a like launch be? We will give no information on this call nor anywhere.” — Mick Farrell, Chief Executive Officer · 2026-08-06 This quarter, nobody asked. The story moved off the device box and onto the cushion, the app, and the consumer channel — which is why the AirSense 11 keyword fell away without anyone noticing.

GLP-1 is a two-year-old theme with a new subplot

The Lilly demand-generation tailwind is not new — it has been a top-decile keyword for ResMed since early 2025, and the "is this a headwind?" debate was pronounced dead in January: “the thesis that this could be a headwind is completely gone. It's a tailwind.” — Michael Farrell, Chief Executive Officer · 2026-01-29 What is new is granularity and the pill form cohort. The claims database now covers 3.3 million de-identified patients: CPAP-plus-GLP-1 patients are 11% more likely to start therapy, 3% more likely to resupply at one year, 7% at three years. On orals, Farrell expects a slightly older, slightly more male demographic — and, in his gut view, a more adherent one. It is a genuinely additive cohort being layered onto a thesis that is otherwise two years stale.

Where this sits against the market

The market's own tape is voting on something entirely different. The biggest twelve-month themes are AI data center, high-bandwidth memory and co-packaged optics; the biggest decliners are software abstractions like "system of record" and "generative AI capabilities." ResMed shares none of that. Its rally is idiosyncratic — a healthcare compounder with a compressed multiple, a divested software asset, and a cash-return story that finally has a balance sheet behind it: effective net cash of $810 million, up 50% year over year. Meanwhile R&D keeps climbing as a share of revenue — R&D of $106 million on $1.46 billion of revenue, about 7.2% — and GAAP gross margin, at 58.8%, sits well under the 62.5% non-GAAP print, a reminder that the productivity pipeline has to outrun electronic-component inflation that management explicitly expects to worsen from here. The honest read: this is a good quarter from a company guiding conservatively into a stock that has already decided the funnel works. The next two quarters — when Indiana distribution costs land, the France fleet refresh turns from tailwind to headwind, and marketing either converts or doesn't — will tell you whether the tape or the CFO was right.